Key result
Intravenous milrinone improved subjective symptoms (47.6% vs 0%) and physical findings (40% vs 0%) within 60 minutes compared to placebo in patients with acute heart failure.
Why the study?
Does intravenous milrinone improve cardiovascular hemodynamics and symptoms in patients with acute heart failure?
Population
106 patients with acute or decompensated heart failure hospitalized in cardiac care units across 33…
Comparison
Intravenous milrinone vs Placebo treatment
Design
RCT, Double-blind
Follow-up
6 hours
Authors
Loading...
Supports short-term symptom relief with IV milrinone in acute HF; confirms RCT efficacy on subjective and physical outcomes.
RCT (n=106)
Double-blind
Yes
Does intravenous milrinone improve cardiovascular hemodynamics and symptoms in patients with acute heart failure?
Absolute Event Rate: 47.6% vs 0%
Seino et al. (1996) conducted an RCT in acute heart failure (n=106). Intravenous milrinone vs. Placebo was evaluated on Improvement in subjective symptoms within 60 mins. Intravenous milrinone improved subjective symptoms (47.6% vs 0%) and physical findings (40% vs 0%) within 60 minutes compared to placebo in patients with acute heart failure.